Media

Algernon Pharmaceuticals updates Phase 2 human testing of Ifenprodil for COVID-19
Apr 03, 2020
Uncategorized

Algernon Pharmaceuticals updates Phase 2 human testing of Ifenprodil for COVID-19

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher …

Equity Insight – Interview with CEO of Algernon Pharmaceuticals
Mar 31, 2020
Uncategorized

Equity Insight – Interview with CEO of Algernon Pharmaceuticals

Today we have the CEO of Algernon Pharmaceuticals (CSE: AGN) (OTCQB: …

WEBCAST: BioPub.co Presents: Algernon Pharmaceuticals (CSE: AGN OTCQB: AGNPF)
Mar 03, 2020
Video

WEBCAST: BioPub.co Presents: Algernon Pharmaceuticals (CSE: AGN OTCQB: AGNPF)

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic Pulmonary fibrosis. (IPF)
Sign up for our News Releases
Head Office
Suite 915 – 700 West Pender Street
Vancouver, BC, Canada • V6C 1G8

Hit enter to search or ESC to close